Quantum-Si Reports Q1 Results, Advances Proteus Development, Secures Cash Runway into 2028

summarizeSummary

Quantum-Si reported mixed first-quarter financial results with low revenue but a better-than-expected net loss, while highlighting significant progress in its Proteus™ instrument development and confirming a strong cash runway into Q2 2028.

check_boxKey Events

• Q1 2026 Financial Results

  Reported revenue of $258,000, a significant decrease from $842,000 in Q1 2025, and a net loss of $21.7 million, which was wider than the $19.2 million loss in Q1 2025 but better than analyst expectations.

• Proteus Development Milestones Achieved

  Announced successful sequencing on integrated Proteus™ instruments, sequenced first customer samples on a prototype system, and confirmed the developmental sequencing kit detects 17 amino acids, progressing towards a commercial launch by the end of 2026.

• Strong Cash Runway Confirmed

  As of March 31, 2026, the company held $190.4 million in cash and investments, which is anticipated to fund operations into the second quarter of 2028.

• Reiterated 2026 Financial Guidance

  Maintained full-year 2026 guidance for approximately $1.0 million in revenue, reflecting strategic tradeoffs to prioritize the Proteus launch and long-term platform adoption.

auto_awesomeAnalysis

This 8-K provides a critical update on Quantum-Si's financial performance and strategic progress. While first-quarter revenue was significantly lower year-over-year and slightly below analyst expectations, the net loss was better than anticipated. The company's focus remains on the commercial launch of its Proteus™ single-molecule protein sequencing platform by the end of 2026, with notable development milestones achieved, including successful sequencing on integrated instruments and early customer sample evaluations. Crucially, the company's cash and investments of $190.4 million provide a substantial runway into the second quarter of 2028, mitigating near-term liquidity concerns and supporting continued R&D investment. Investors should monitor further Proteus development updates and the market reception of early access programs as the company navigates this transition year.